Relative risk of death in the SMART study

The Lancet Infectious Diseases

Volumn 9, Issue 12, 2009, Pages 724-725

  Grund, Birgit ^a   Neuhaus, Jacqueline ^a   Phillips, Andrew ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT;

CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONSERVATIVE TREATMENT; DEMOGRAPHY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ABUSE; LETTER; MEDICAL RESEARCH; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; UNITED STATES;

EID: 71549166964     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70302-0     Document Type: Letter

References (3)

1. Stebbing J., and Dalgleish A. Not so SMART?. Lancet Infect Dis 9 (2009) 268-269
2. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
3. Kuller L., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5 (2008) e203